PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.87%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.01%. Joel Greenblatt would investigate if growth quality matches quantity.
3.10%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.96%. Jim Chanos would check for structural cost disadvantages.
12.17%
Positive growth while Medical - Pharmaceuticals median is negative. Peter Lynch would examine competitive advantages.
6.96%
Margin expansion while Medical - Pharmaceuticals median declines. Peter Lynch would examine competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-100.00%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
5.14%
Operating expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
3.45%
Total costs growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
6.52%
Interest expense change of 6.52% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
-4.37%
D&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency.
121.19%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 9.01%. Joel Greenblatt would investigate advantages.
110.92%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 5.51%. Joel Greenblatt would investigate advantages.
49.18%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 5.02%. Joel Greenblatt would investigate advantages.
42.25%
Operating margin growth exceeding 1.5x Medical - Pharmaceuticals median of 1.06%. Joel Greenblatt would investigate advantages.
3364.29%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 5.50%. Jim Chanos would check for issues.
55.15%
Pre-tax income growth exceeding 1.5x Medical - Pharmaceuticals median of 13.63%. Joel Greenblatt would investigate advantages.
47.94%
Pre-tax margin growth exceeding 1.5x Medical - Pharmaceuticals median of 9.67%. Joel Greenblatt would investigate advantages.
475.92%
Tax expense growth exceeding 1.5x Medical - Pharmaceuticals median of 20.80%. Jim Chanos would check for issues.
14.74%
Net income growth near Medical - Pharmaceuticals median of 14.42%. Charlie Munger would verify industry dynamics.
9.41%
Net margin growth near Medical - Pharmaceuticals median of 9.98%. Charlie Munger would verify industry dynamics.
14.74%
EPS growth near Medical - Pharmaceuticals median of 14.82%. Charlie Munger would verify industry dynamics.
14.74%
Diluted EPS growth near Medical - Pharmaceuticals median of 14.82%. Charlie Munger would verify industry dynamics.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.24%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.29%. Seth Klarman would investigate strategy.